Videos – Barrow Hanley
On International Women’s Day, a few of Barrow Hanley’s women leaders share their stories and advice as we look to encourage and inspire the next generation of women investment professionals: https://www.barrowhanley.com/the-value-proposition-multimedia-insights?wchannelid=62cpn22v99&wmediaid=uk1rkzmq7r At Barrow Hanley, we believe diverse teams create better outcomes. That’s why we are committed to employing, empowering and advancing women in roles across…
Latest
Barrow Hanley
3Q22 Review & Outlook: Diversified Large Cap Value
Portfolio Manager Mark Giambrone provides a review of the Barrow Hanley Diversified Large Cap Value portfolio’s performance for 3Q22 and shares his expectations for Value investing over the near and intermediate term. More about Mark Giambrone, Senior Managing Director, Equity Portfolio Manager / Analyst
Barrow Hanley
Asset TV Masterclass: Investing in Emerging Markets
What makes emerging markets an attractive investment given the broader economic risks? Head of International Equities Rand Wrighton discusses on Asset TV Masterclass. More about Rand S. Wrighton Jr., CFA, Senior Managing Director, Equity Portfolio Manager / Analyst
Barrow Hanley
What makes Barrow Hanley a proven, principled partner_
What values best describe Barrow Hanley? What do our employees enjoy the most about working at the firm? Hear more from the team, including CEO Cory Martin and Founding Director and Portfolio Manager James Barrow. More about Cory Martin, CEO, Executive Director, Equity Portfolio Manager
Barrow Hanley
Barrow Hanley Credit Partners: Lens on Credit Series | Credit Markets: Then vs. Now
Credit Markets: Then vs. Now Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager
Barrow Hanley
Barrow Hanley Credit Partners: Lens on Credit Series | Fed Moves Expected Impacts on Leveraged Finance Markets
Fed Moves: Expected Impacts on Leveraged Finance Markets Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager
Barrow Hanley
Barrow Hanley Credit Partners: Lens on Credit Series | HY and BL: How Do They Fit Into a Broader Portfolio?
HY and BL: How Do They Fit Into a Broader Portfolio How do high yield and bank loan securities fit in broader portfolios and how do we expect them to perform in the current environment? More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…